Jean-Philippe Camdessanché

29PUBLICATIONS
129CO-AUTHORS
Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Peripheral nervous systemPredictive and prognostic markersRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Aug 14, 2026
Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

|May 20, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

|May 15, 2026
Clinical, Electrophysiological, and Neuropathological Features of Peripheral Neuropathies in People With T-Cell Lymphoproliferative Disorder.

|May 05, 2026
Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.

|Apr 22, 2026
Characteristics of Patients with Myasthenia Gravis in the French Rare Disease Registry.

|Jan 23, 2026
Myasthenia Gravis Outcomes After Use of Statins and Other Contraindicated Treatments: Results From the French National Insurance Database.

Guilhem Solé, Jean Philippe Camdessanché, Shahram Attarian

Pageof 5

Frequent Collaborators

9 joint publications

Guillaume Mathey

8 joint publications

Jonathan Ciron

8 joint publications

Christine Lebrun-Frenay

7 joint publications

Bertrand Bourre